News

There is always something new at ImmunoGenesis. Stay on top of the latest.

Press Releases

ImmunoGenesis Doses First Patient in Phase 1a/1b Clinical Trial of IMGS‑001 in Relapsed or Refractory Advanced Solid Tumors

ImmunoGenesis today announced the first patient has been dosed in the company’s Phase 1a/1b clinical trial of its lead candidate, IMGS-001, at The University of Texas MD Anderson Cancer Center in Houston, Texas. IMGS-001 is a dual-specific programmed cell death 1 ligand 1 (PD-L1)/programmed cell death 1 ligand 2 (PD-L2) antibody engineered with cytotoxic function designed to treat cold, immune-excluded tumors, which are resistant to existing immunotherapy.

Read more
ImmunoGenesis and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Trial of IMGS-001 for Relapsed or Refractory Advanced Solid Tumors

ImmunoGenesis and Cancer Focus Fund, LP, announce that Cancer Focus Fund plans to invest $4.5 million to support the Phase 1a/1b clinical trial of ImmunoGenesis’ lead candidate, IMGS-001. The investment will support the portion of the IMGS-001 Phase 1a/1b multi-site clinical trial being conducted at MD Anderson. It coincides with ImmunoGenesis’ Series A financing, which is expected to close in the third quarter.

Read more

Key Publications

Development of IMGS-001, a novel anti–PD-L1/PD-L2 dual-specific, multifunctional antibody, to treat immune-excluded tumors.

C Gagliardi, A Salameh, P Blezinger, M Hemberger, C Schweizer, J Barlow, M Curran, F Pericle. Poster presented at: Society for Immunotherapy of Cancer Annual Meeting; November 8-12, 2022; Boston, MA.

View poster
Preclinical characterization of IMGS-001, a dual-antagonist anti–PD-L1 and PD-L2 antibody with effector function, to treat patients resistant to immune checkpoint blockade.

A Salameh, C Gagliardi, P Blezinger, M Hemberger, C Schweizer, J Barlow, M Curran, F Pericle. Poster presented at: Society for Immunotherapy of Cancer Annual Meeting; November 8-12, 2022; Boston, MA.

View poster
Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma.

Burrack, AL, Spartz, EJ, Raynor, JF, Wang, I, Olson, M, Stromnes, IM. Cell Reports. 2019.

View publication
Genomic biomarkers in relation to PD-1 checkpoint blockade response.

Seiwert, TY, Cristescu, R, Kaufman, DR, et al. Journal of Clinical Oncology. 2018.

View publication
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.

Yearley, JH, Gibson, C, Yu, N, Moon, C, Murphy, E, McClanahan, T, et al. Clinical Cancer Research. 2017.

View publication
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.

Curran, MA, Montalvo, W, Yagita, H, Allison, JP. PNAS. 2010.

View publication

Upcoming events

There are no upcoming events scheduled at this time. Sign up to receive notices about upcoming events and press releases.